Paris Public Hospitals Group and Magnisense partner to develop tests
for cardiovascular diseases
9 October 2014
French hospital group AP-HP, (Assistance Publique-Hôpitaux de
Paris), and diagnostics technology developer Magnisense have signed
a partnership agreement to develop rapid portable diagnostic tests
for cardiovascular diseases.
Under this partnership, AP‑HP will provide Magnisense with
biological samples from cohorts of patients suffering from
cardiovascular diseases and participate in validating tests.
AP-HP also grants Magnisense a license option agreement for the
global and exclusive commercial exploitation of one of its patents
on postpartum hemorrhage in women. Magnisense and Lariboisière
Hospital are working together to develop and record proprietary
emergency diagnostic tests for myocardial infarction that meet the
requirements of hospital emergency physicians, resuscitation
specialists, anaesthesiologists and cardiologists.
These quantitative tests are based on whole blood, take 15
minutes and are robust, portable, economical and WiFi-enabled. The
instrument designed by Magnisense based on its proprietary MIAtek
technology is used to conduct the tests. Magnisense says it aims to
commercialize its first diagnostic tests, starting in France within
the next few months.
These same tests can also be recorded and commercialized to
"predict postpartum hemorrhage in women", one of the most common
causes of death after childbirth. The tests, which contribute in
establishing a predictive score for the risk of postpartum
hemorrhage — a technique patented and validated in two cohorts of
patients — will be developed through the option license agreement
for commercial exploitation granted by AP-HP to Magnisense.
"The development of reliable, inexpensive and easy-to-use
point-of-care tools for biological measurement meets a real need.
Biomarkers are now used on a day-to-day basis, both to help in
diagnosis and stratify risk as well as to guide the treatment of the
patients that we care for every day, in particular patients at high
cardiovascular risk," explains Prof. Alexandre Mebazaa, Head of the
Anesthesia and Reanimation Department at the Saint-Louis-Lariboisière
"Our proprietary emergency diagnostic tests for cardiovascular
diseases offer a concrete response to major public health and
economic concerns throughout the world. We are delighted about this
partnership with Professor Alexandre Mebazaa's team and AP-HP. It
enables Magnisense to ensure the safety of the development and
validation quality of its tests," adds Lyse Santoro, Chief Executive
Officer of Magnisense.